Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px
Document › Details

BCN Health Venture Partners S.L. (BHV Partners). (12/22/23). "Press Release: BHV Partners Appoints Albert Mascarell as New CEO". Barcelona.

Organisations Organisation BCN Health Venture Partners S.L. (BHV Partners)
  Group BHV Partners (BCN Health Venture Partners) (Group)
  Organisation 2 Plebiotic S.L.
Products Product venture capital
  Product 2 HEALTH (HUMAN)
Persons Person Mascarell, Albert (BHV Partners 202401– CEO + Partner before Plebiotic + Laboratorios BioInnove + aScidea + Fagron)
  Person 2 Escarré, Gemma (Gemma Escarré Communications 202112 before Biocat 201208 Web Editor)

The venture builder specialized in health has also bolstered its Board of Directors, bringing in Xavier Carbonell and Eva Berenguer, in addition to Albert Mascarell

BHV Partners, a venture builder that specializes in creating disruptive start-ups in the health sector, has appointed entrepreneur Albert Mascarell as its new CEO, effective January 1, 2024.

Mascarell has more than 15 years of experience as founder and CEO of science start-ups like Plebiotic, Laboratorios BioInnove and aScidea, the latter two acquired by multinational pharmaceutical corporations. He also held positions of leadership at Fagron Genomics and the Fagron Group between 2018 and January 2023. Since 2015, he has been a start-up consultant accredited by ACCIÓ (Government of Catalonia), a mentor and professor at the UPF Barcelona School of Management, and an adviser to various start-ups and spinoffs.

Marta Príncep, Co-Founder and outgoing CEO of BHV Partners, said, “It has been a privilege to lead BHV Partners since it was established in 2019. Albert has extensive knowledge of how to create start-ups and drive their growth through to market, merger or acquisition, which will be of great value to BHV Partners as a venture builder and to the science and entrepreneurship community.” Príncep will remain on the Board of Directors and will take charge of Director of Consultancy, a strategic business division for BHV Partners that requires an executive profile with broad experience in the sector.

Albert Mascarell said, “My passion and professional mission is to build and help others build their companies based on science and technology of excellence in order to address unmet medical needs. I’m happy to be joining BHV Partners as a partner and CEO because it is a benchmark venture builder in the healthcare ecosystem with an important plan for growth. There are exciting times ahead.”

Appointments to the Board of Directors

BHV Partners has expanded its Board of Directors, bringing Xavier Carbonell and Eva Berenguer on board in addition to Albert Mascarell. The knowledge of these experts will complement and bolster that of current board members Albert G. Zamora (chairman), Marta Príncep and Joaquim Trias.

Xavier Carbonell has been CEO of the Palex Group since 2007 and is a member of the Executive Board of the Spanish Federation of Healthcare Technology Companies (Fenin) and the Spanish Chamber of Commerce Innovation and Competitiveness Committee. He was previously head of Oncology at Amgen Spain and Medical Director and Head of Marketing for Novartis Oncology.

Eva Berenguer has been Chief Financial & Compliance Officer at SOM Biotech since 2022. Her more than 20 years in the business, mostly in the United States, have given her a proven record of success in organizational development, project management, corporate culture change, and internal and external auditing. She has previously held executive positions at Zimmer Biomet, Armacell, Robert Bosch Automotive Steering LLC and Baxter Healthcare.

“It is an honor to have Xavier and Eva on our Board of Directors. Their experience will be extremely valuable in making the most of BHV Partners’ potential,” noted Albert G. Zamora, chairman of the BHV Partners Board.

About BHV Partners

BHV Partners is an experienced venture builder that creates start-ups to transform the top research and technology from universities, hospitals and research centres into disruptive health solutions.

Unlike accelerators and incubators, BHV Partners selects projects that respond to unmet medical needs, creates a joint start-up with the scientists and together define the best strategy at technological, corporate and funding level. We work hands-on with the scientific team throughout the life cycle of the start-up, helping them growth, diminishing the risk and improving the opportunities. BHV Partners currently has a portfolio of 7 start-ups valued at €23 million and two more in process, scheduled to launch in 2024. BHV Partners has an international network of over 70 partners and senior experts who advise and mentor the projects.

BHV Partners also offers strategy and consulting services for technology transfer offices at research centers and hospitals, entrepreneurs and start-ups, the biomedical industry and funds (VC and family offices).

More information:


Media contact:

Gemma Escarré Comms
M +34 667 76 15 24
Follow us on LinkedIn and Twitter

Record changed: 2024-01-31


Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x300px

» top